Access the full text.
Sign up today, get DeepDyve free for 14 days.
Planer (2011)
Comparison of everolimus- and paclitaxel-eluting stents in patients with acute and stable coronary syndromes: Pooled results from the SPIRIT (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (A Trial of Everolimus-Eluting Stents and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice) trialsJACC Cardiovasc Interv, 4
L. Mauri, Wen-hua Hsieh, J. Massaro, K. Ho, R. D'Agostino, D. Cutlip (2007)
Stent thrombosis in randomized clinical trials of drug-eluting stents.The New England journal of medicine, 356 10
G. Stone, A. Rizvi, W. Newman, Kourosh Mastali, John Wang, R. Caputo, Julie Doostzadeh, Sherry Cao, C. Simonton, K. Sudhir, A. Lansky, D. Cutlip, D. Kereiakes (2010)
Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease.The New England journal of medicine, 362 18
A. Kastrati, J. Mehilli, J. Dirschinger, F. Dotzer, H. Schühlen, Franz‐Josef Neumann, Martin Fleckenstein, Conrad Pfafferott, M. Seyfarth, A. Schömig (2001)
Intracoronary Stenting and Angiographic Results: Strut Thickness Effect on Restenosis Outcome (ISAR-STEREO) TrialCirculation: Journal of the American Heart Association, 103
R. Vieira, W. Hueb, B. Gersh, E. Lima, A. Pereira, P. Rezende, C. Garzillo, A. Hueb, D. Favarato, P. Soares, J. Ramires, R. Filho (2012)
Effect of Complete Revascularization on 10-Year Survival of Patients With Stable Multivessel Coronary Artery Disease: MASS II TrialCirculation, 126
Elvin Kedhi, K. Joesoef, E. Mcfadden, J. Wassing, P. Smits (2010)
Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trialThe Lancet, 375
K. Rasmussen, M. Maeng, A. Kaltoft, P. Thayssen, H. Kelbæk, H. Tilsted, U. Abildgaard, E. Christiansen, T. Engstrøm, L. Krusell, J. Ravkilde, P. Hansen, K. Hansen, S. Abildstrom, J. Aarøe, J. Jensen, S. Kristensen, H. Bøtker, M. Madsen, S. Johnsen, L. Jensen, H. Sørensen, L. Thuesen, J. Lassen (2010)
Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trialThe Lancet, 375
M. Mahmoudi, C. Delhaye, K. Wakabayashi, I. Ben‐dor, Manuel Gonzalez, Gabriel Maluenda, M. Gaglia, R. Torguson, Zhenyi Xue, A. Syed, S. Collins, W. Suddath, K. Kent, L. Satler, A. Pichard, R. Waksman (2011)
CLINICAL OUTCOMES FOLLOWING UNRESTRICTED USE OF THE EVEROLIMUS-ELUTING STENT AS COMPARED WITH PACLITAXEL- AND SIROLIMUS-ELUTING STENTSJournal of the American College of Cardiology, 57
M. Farkouh, Michael Domanski, Lynn Sleeper, F. Siami, G. Dangas, Michael Mack, May Yang, D. Cohen, Yves Rosenberg, Scott Solomon, Akshay Desai, B. Gersh, Ch B, E. Magnuson, Alexandra Lansky, R. Boineau, Jesse Weinberger, K. Ramanathan, J. Sousa, J. Rankin, Balram Bhargava, John Buse, W. Hueb, Craig Smith, Victoria Muratov, S. Bansilal, King Iii, Michel Bertrand, Valentin Fuster, Michael Cardio (2012)
Strategies for multivessel revascularization in patients with diabetes.The New England journal of medicine, 367 25
Elvin Kedhi, M. Gomes, B. Lagerqvist, J. Smith, E. Omerovic, S. James, J. Harnek, G. Olivecrona (2012)
Clinical impact of second-generation everolimus-eluting stent compared with first-generation drug-eluting stents in diabetes mellitus patients: insights from a nationwide coronary intervention register.JACC. Cardiovascular interventions, 5 11
D. Muller, D. Muller, E. Topol, E. Topol, Stephen Ellis, Stephen Ellis, K. Sigmon, K. Sigmon, Kerry Lee, Kerry Lee, R. Califf, R. Califf (1991)
Multivessel coronary artery disease: a key predictor of short-term prognosis after reperfusion therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group.American heart journal, 121 4 Pt 1
P. Serruys, Y. Onuma, S. Garg, P. Vranckx, B. Bruyne, M. Morice, A. Colombo, C. Macaya, G. Richardt, J. Fajadet, C. Hamm, M. Schuijer, T. Rademaker, Kristel Wittebols, H. Stoll (2010)
5-year clinical outcomes of the ARTS II (Arterial Revascularization Therapies Study II) of the sirolimus-eluting stent in the treatment of patients with multivessel de novo coronary artery lesions.Journal of the American College of Cardiology, 55 11
R. Virmani, F. Liistro, G. Stanković, C. Mario, M. Montorfano, A. Farb, F. Kolodgie, A. Colombo (2002)
Mechanism of Late In-Stent Restenosis After Implantation of a Paclitaxel Derivate–Eluting Polymer Stent System in HumansCirculation: Journal of the American Heart Association, 106
G. Nakazawa, E. Ladich, A. Finn, R. Virmani (2008)
Pathophysiology of vascular healing and stent mediated arterial injury.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 4 Suppl C
E. Sperry, K. Miller, B. Huibregtse, B. Poff (2008)
Neointimal suppression in response to the PROMUS everolimus-eluting coronary stent compared to the bare Liberté stent in the 30% overstretch porcine coronary injury model at 10, 30, and 90 daysCardiovascular Revascularization Medicine, 9
Aaron From, Firas Badarin, Stephen Cha, C. Rihal (2010)
Percutaneous coronary intervention with drug-eluting stents versus coronary artery bypass surgery for multivessel coronary artery disease: a meta-analysis of data from the ARTS II, CARDia, ERACI III, and SYNTAX studies and systematic review of observational data.Eurointervention, 6
K. Kolandaivelu, R. Swaminathan, W. Gibson, V. Kolachalama, Kim-Lien Nguyen-Ehrenreich, V. Giddings, Leslie Coleman, Gee Wong, E. Edelman (2011)
Stent Thrombogenicity Early in High-Risk Interventional Settings Is Driven by Stent Design and Deployment and Protected by Polymer-Drug CoatingsCirculation, 123
G. Levine, E. Bates, J. Blankenship, S. Bailey, J. Bittl, B. Cercek, C. Chambers, S. Ellis, R. Guyton, S. Hollenberg, U. Khot, R. Lange, L. Mauri, R. Mehran, I. Moussa, D. Mukherjee, B. Nallamothu, H. Ting (2011)
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions.Journal of the American College of Cardiology, 58 24
Kastrati (2001)
Intracoronary stenting and angiographic results: Strut thickness effect on restenosis outcome (ISAR-STEREO) trialCirculation, 103
M. Joner, G. Nakazawa, A. Finn, Shawn Quee, Leslie Coleman, Eduardo Acampado, P. Wilson, K. Skorija, Qi Cheng, Xin Xu, H. Gold, F. Kolodgie, R. Virmani (2008)
Endothelial cell recovery between comparator polymer-based drug-eluting stents.Journal of the American College of Cardiology, 52 5
S. Brener, B. Lytle, I. Casserly, J. Schneider, E. Topol, M. Lauer (2004)
Propensity Analysis of Long-Term Survival After Surgical or Percutaneous Revascularization in Patients With Multivessel Coronary Artery Disease and High-Risk FeaturesCirculation: Journal of the American Heart Association, 109
Mahmoudi (2011)
Clinical outcomes following unrestricted use of the everolimus-eluting stent as compared with paclitaxel- and sirolimus-eluting stentsCardiovasc Revasc Med, 12
D. Kereiakes, K. Sudhir, J. Hermiller, P. Gordon, Joanne Ferguson, M. Yaqub, P. Sood, Xiaolu Su, S. Yakubov, A. Lansky, G. Stone (2010)
Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients undergoing multilesion and multivessel intervention: the SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With DeJACC. Cardiovascular interventions, 3 12
G. Levine, E. Bates, J. Blankenship, S. Bailey, J. Bittl, B. Cercek, C. Chambers, S. Ellis, R. Guyton, S. Hollenberg, U. Khot, R. Lange, L. Mauri, R. Mehran, I. Moussa, D. Mukherjee, B. Nallamothu, H. Ting, A. Jacobs, Jeffrey Anderson, N. Albert, M. Creager (2011)
ACCF/AHA/SCAI Practice Guideline 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions
D. Kereiakes, P. Smits, Elvin Kedhi, H. Parise, M. Fahy, P. Serruys, G. Stone (2011)
Predictors of death or myocardial infarction, ischaemic-driven revascularisation, and major adverse cardiovascular events following everolimus-eluting or paclitaxel-eluting stent deployment: pooled analysis from the SPIRIT II, III, IV and COMPARE trials.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 7 1
L. Räber, P. Jüni, E. Nüesch, B. Kalesan, P. Wenaweser, Aris Moschovitis, A. Khattab, M. Bahlo, M. Togni, S. Cook, R. Vogel, C. Seiler, B. Meier, S. Windecker (2011)
Long-term comparison of everolimus-eluting and sirolimus-eluting stents for coronary revascularization.Journal of the American College of Cardiology, 57 21
P. Serruys, M. Morice, A. Kappetein, A. Colombo, D. Holmes, M. Mack, E. Ståhle, T. Feldman, M. Brand, E. Bass, N. Dyck, Katrin Leadley, K. Dawkins, F. Mohr, Boston Scientif (2009)
Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease.The New England journal of medicine, 360 10
Objective This study aimed to compare the safety and efficacy of everolimus‐eluting stents (EES) to first‐generation drug‐eluting stents (DES) in multivessel disease (MVD). Background Second‐generation EES have demonstrated superiority over first‐generation DES for single‐vessel disease, although the merits of EES in MVD are less established. Methods A cohort of 1,285 patients (3,124 lesions) with ≥2 diseased vessels were treated with either first‐generation DES (n = 1,002) or EES (n = 283). The rates of death, myocardial infarction, target lesion revascularization, target vessel revascularization, definite stent thrombosis, and major adverse cardiac events (MACE), defined as the combined incidence of target vessel revascularization, death, and non‐fatal myocardial infarction, were compared at 1 year. Results Baseline characteristics were similar except for a lower left ventricular ejection fraction and a lower incidence of stable angina pectoris in the first‐generation DES group (P = 0.001 and 0.013, respectively). At 1 year, the MACE rate was lower in the EES group (9.5P% vs. 15.7%; P = 0.01). Multivariable analysis demonstrated that EES use predicted a higher chance of freedom from MACE at 1 year (hazard ratio 0.58 (0.38–0.87); P = 0.009; 95% confidence interval). Conclusions The use of EES in patients with MVD is safe with signals for improved effectiveness compared to first‐generation DES. Randomized trials comparing new‐generation DES to coronary artery bypass grafting surgery are warranted.
Journal of Interventional Cardiology – Wiley
Published: Dec 1, 2013
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.